ARQT · Arcutis Biotherapeutics, Inc.
$28.26
+0.73 (+2.65%)
At close · Jul 21
Market Cap
$3.53B
Shares
125.08M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$376.07M
+91.3%
FY2025
Net Income
-$16.14M
+88.5%
FY2025
Gross Margin
90.24%
0pp
FY2025
Operating Margin
-3.25%
+62.1pp
FY2025
Diluted EPS
-$0.13
+88.8%
FY2025
Operating Cash Flow
-$5.63M
+95%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| $480M – $495M | $415.62M | $376.07M | $196.54M | $59.61M | $3.69M | $0 | $0 | — | — | |
| — | $37.65M | $36.7M | $19.13M | $4.99M | $754K | $0 | — | — | — | |
| — | $377.98M | $339.38M | $177.41M | $54.62M | $2.93M | $0 | — | — | — | |
| — | — | 90.24% | 90.27% | 91.63% | 79.54% | — | — | — | — | |
| — | $90.14M | $77.05M | $76.42M | $110.58M | $182.44M | $145.56M | $115.31M | $36.52M | $17.94M | |
| — | — | — | — | — | $122.12M | $60.97M | $21.34M | $6.61M | $1.8M | |
| — | $284.63M | $274.55M | $229.39M | $185.15M | $122.12M | $60.97M | — | — | — | |
| — | — | $4.67M | $1.96M | $750K | $312K | $0 | $0 | — | — | |
| — | $297.4M | — | — | — | $305.31M | $206.53M | $136.65M | $43.13M | $19.74M | |
| — | $412.41M | $388.3M | $324.94M | $300.71M | $305.31M | $206.53M | — | — | — | |
| — | $3.21M | -$12.23M | -$128.4M | -$241.1M | -$301.63M | -$206.53M | -$136.65M | -$43.13M | -$19.74M | |
| — | — | -3.25% | -65.33% | -404.49% | -8183.04% | — | — | — | — | |
| — | $13.47M | $12.08M | $27.17M | $29.71M | $15.65M | $0 | $0 | — | — | |
| — | $230K | $443K | $47K | -$731K | -$9.83M | $173K | $967K | $1.14M | $480K | |
| — | $985K | $1.17M | $647K | $3.11M | $0 | $0 | $0 | $0 | $0 | |
| — | -$2.38M | -$16.14M | -$140.04M | -$262.14M | -$311.46M | -$206.36M | -$135.68M | -$42M | -$19.26M | |
| — | — | -4.29% | -71.25% | -439.79% | -8449.76% | — | — | — | — | |
| — | -$2.75M | -$16.18M | -$140.05M | -$261.05M | -$312.29M | -$206.61M | -$135.68M | -$42M | -$19.26M | |
| USD/shares | — | — | -$0.13 | -$1.16 | -$3.78 | -$5.66 | -$4.18 | -$3.80 | -$22.78 | — |
| USD/shares | — | — | -$0.13 | -$1.16 | -$3.78 | -$5.66 | -$4.18 | -$3.80 | -$22.78 | — |
| shares | — | — | 127.23M | 120.96M | 69.31M | 55.03M | 49.41M | 35.67M | 1.84M | 1.24M |
| shares | — | — | 127.23M | 120.96M | 69.31M | 55.03M | 49.41M | 35.67M | 1.84M | 1.24M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
8.68×
Biotechnology median 8.68×
EV/EBIT
1,123.41×
Biotechnology median 26.35×
P/E (TTM)
—
Biotechnology median 7.21×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $376,072,000 | $196,542,000 | $59,606,000 | $3,686,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| ZORYVE Foam | $181,892,000 | $71,539,000 | $0 | $0 | — | — |
| ZORYVE Cream 0.3 | $120,995,000 | $85,082,000 | $29,186,000 | $3,686,000 | — | — |
| ZORYVE Cream 0.15 | $68,274,000 | $9,921,000 | $0 | $0 | — | — |
| ZORYVE Cream 0.05 | $911,000 | $0 | $0 | — | — | — |
| Other Revenue | — | — | — | — | $0 | — |
| Product | — | — | — | — | $0 | $0 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | -$12,227,000 | -$128,397,000 | -$241,101,000 | -$301,627,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | -3.3% | -65.3% | -404.5% | -8183% |
Key facts
CIK
1787306
CUSIP
03969K108
13F (30d)
20 filings
20 filers
Visit website
Investor relations